亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

湖北正興源化工有限公司  

中間體,原料,精細化工

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:楊嬌
  • 電話:18827658064
  • 郵件:2151566506@qq.com
  • 傳真:027-87879183
  • QQ:2151566506
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 生產利伐沙班
生產利伐沙班
單價 1.00 / kg對比
銷量 暫無
發貨 湖北武漢市付款后3天內
庫存 1kg起訂1kg
品牌 湖北正興源
電話 027-87879183
手機 18827658064
QQ 2151566506
過期 長期有效
更新 2016-09-28 16:02
 
詳細信息
 伐沙班
99.5%企標
抗血栓藥物
中文名稱: 利伐沙班
中文同義詞: 5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代嗎啉-4-基)苯基)-1,3-惡唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班;5-氯-N-[[(5S)-2-氧代-3-[4-(3-氧代-4-嗎啉基)苯基]-5-惡唑基]甲基]-2-噻吩甲酰胺;利伐沙班, 5-氯-N-(((5S)-2-氧代-3-(4-(3-氧代嗎啉-4-基)苯基)-1,3-惡唑啉-5-基)甲基)噻吩-2-甲酰胺;利伐沙班-D4;立伐沙班;RIVAROXABAN 利伐沙班;立伐沙班原料藥
英文名稱: Rivaroxaban
英文同義詞: 5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide;BAY 59-7939;Rivaroxaban;5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl];Xarelto;(S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide;Rivaroxaban (BAY59-7939)
CAS號: 366789-02-8
分子式: C19H18ClN3O5S
分子量: 435.88
EINECS號:
相關類別: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium *pounds;原料藥;科研試劑;API;醫藥類別;Inhibitor;Rivaroxaban;利伐沙班;醫藥中間體;其他科研原料藥;利伐沙班中間體;醫藥原料;中間體;Pharmaceutical raw materials;小分子抑制劑;Inhibitors;小分子抑制劑,天然產物;抗血栓藥物;惡唑啉;噻吩


 
湖北正興源化工,華中地區大型原料生產基地,湖北醫藥化工原料誠信供應商??!
優質現貨,出廠價格直銷,可詢價訂單
用高標準,高效率生產高質量的產品,這是正興源人一貫的宗旨??!
與客戶的共贏,是我們的發展目標。正興源化工,最值得您依賴的合作伙伴!!
©2025 湖北正興源化工有限公司 版權所有   技術支持:化工網   訪問量:14137  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |